Müller Sandra, Kehm Roland, Handermann Michaela, Jakob Nurith J, Bahr Udo, Schröder Björn, Darai Gholamreza
Abteilung Virologie, Hygiene-Institut der Universität Heidelberg, Im Neuenheimer Feld 324, 69120, Heidelberg, Germany.
Virus Genes. 2005 Mar;30(2):279-96. doi: 10.1007/s11262-004-5634-1.
The objective of this study was to investigate the molecular mechanisms of neurobiological processes involved in the degeneration of the central nervous system. The bovine spongiform encephalopathy (BSE) was used as experimental model system for investigation of transmissible spongiform encephalopathy (TSE). The experimental strategy was to evaluate the possibility for protection of bovine PrP(C) transgenic mice against a bovine PrP(Sc) infection by DNA vaccination using the complete or partial cDNA sequences of the bovine prion protein. Three recombinant plasmids pCR3.1-EX-PrP-BSE-C20 (C20), pCR3.1-EX-PrP-BSE-90-235-C4 (C4), and pCR3.1-EX-PrP-BSE-106-131-C14 (C14) were constructed. These mammalian expression vectors harbor complete (C20) or partial (C4 and C14) cDNA sequences of the Bos taurus PrP(C) (BTPrP(C)) encoding for amino acid residues 1-264 (C20), 90-235 (C4), and 106-131 (C14) of the BTPrP(C). Transgenic mice harboring and expressing BTPrP(C) were generated using the donor strain C57/CBA, receptor strain Swiss mouse, and recombinant plasmid MoPrPXho-boPrP. Crossing of positive transgenic mice to bovine PrP and negative to murine PrP with 129/OLA (murine PrP-/-) and C57BL6x129/OLA (murine PrP+/-) mice was carried out to amplify the colony of transgenic mice termed bovine PrP(C) transgenic Swiss mice (BTPrP-TgM). The capabilities of C20, C4, and C14 to express the corresponding cDNA sequence of BTPrP(C) in vitro and in vivo were confirmed prior to DNA vaccination of the BTPrP-TgM using NIH 3T3 cells and BALB/c mice, respectively. In order to prove the capability of the constructed expression vectors to protect BTPrP-TgM in vivo against a BSE infection 80 female BTPrP-TgM were vaccinated intramuscularly and subcutaneously with DNA of the plasmids C20, C4, C14, and parental vector pCR3.1 (100 microg DNA corresponding to about 26-30 pmol DNA/animal and application) in four groups (each consists of 20 animals). DNA vaccination was followed by three additional boosters. The vaccinated animals (15 animals of each group) were challenged twice per oral with homogenates of brain material obtained from BSE cattle containing the infectious PrP(Sc) (100 microl/animal which corresponds to 15 mg of a 15% brain homogenate). The first and second challenge experiments were performed 76-83 and 181 days post DNA vaccination, respectively. A part of the vaccinated animals (3-5 animals of each group) that served as internal negative control were mock infected using the brain homogenate of healthy cattle or Phosphate saline buffer (PBS). A variety of symptoms and clinical pictures were observed during the monitoring of DNA vaccinated animals. However, the observed diseases seem to be similar in all experimental animal groups. After an observation period of 14 months post the second challenge experiment the remaining animals (some animals died or were sacrificed when moribund during the study) were sacrificed after expiration of the experimental schedule. The right hemisphere of the brain and a half of the spleen tissue of the individual animals were used for detection of PrP(Sc) by Western blot analysis. The misfolded bovine PrP(Sc) was not detected in the brain or spleen tissues of those animals that were vaccinated with DNA of C20, which was able to express the complete bovine PrP(C) protein in vitro and in vivo. In contrast, the bovine PrP(Sc) was detected in the brain or spleen tissues of animals that were DNA vaccinated with DNA of the parental vector pCR3.1, with DNA of C4, or with DNA of C14. The results of these studies underline that the constructed expression vector C20 possesses the protective capacity to inhibit the formation of misfolded bovine PrP(Sc) in BTPrP-TgM under the conditions used. A delay of occurrence of TSE-specific symptoms in the majority of the vaccinated animals seems to be due to the prolonged incubation time of BSE infection.
本研究的目的是调查中枢神经系统变性过程中涉及的神经生物学过程的分子机制。牛海绵状脑病(BSE)被用作研究传染性海绵状脑病(TSE)的实验模型系统。实验策略是通过使用牛朊病毒蛋白的完整或部分cDNA序列进行DNA疫苗接种,评估牛PrP(C)转基因小鼠抵抗牛PrP(Sc)感染的可能性。构建了三种重组质粒pCR3.1-EX-PrP-BSE-C20(C20)、pCR3.1-EX-PrP-BSE-90-235-C4(C4)和pCR3.1-EX-PrP-BSE-106-131-C14(C14)。这些哺乳动物表达载体含有牛PrP(C)(BTPrP(C))的完整(C20)或部分(C4和C14)cDNA序列,分别编码BTPrP(C)的氨基酸残基1-264(C20)、90-235(C4)和106-131(C14)。使用供体品系C57/CBA、受体品系瑞士小鼠和重组质粒MoPrPXho-boPrP产生携带并表达BTPrP(C)的转基因小鼠。将阳性转基因小鼠与129/OLA(小鼠PrP-/-)和C57BL6x129/OLA(小鼠PrP+/-)小鼠进行杂交,这些小鼠对牛PrP呈阳性而对小鼠PrP呈阴性,以扩增转基因小鼠群体,称为牛PrP(C)转基因瑞士小鼠(BTPrP-TgM)。在使用NIH 3T3细胞和BALB/c小鼠对BTPrP-TgM进行DNA疫苗接种之前,分别在体外和体内证实了C20、C4和C14表达BTPrP(C)相应cDNA序列的能力。为了证明构建的表达载体在体内保护BTPrP-TgM抵抗BSE感染的能力,将80只雌性BTPrP-TgM分为四组(每组20只动物),分别通过肌肉注射和皮下注射接种质粒C20、C4、C14和亲本载体pCR3.1的DNA(100μg DNA,相当于约26-30pmol DNA/动物和接种量)。DNA疫苗接种后进行另外三次加强免疫。对接种疫苗的动物(每组15只动物),每次经口用含有感染性PrP(Sc)的BSE病牛脑匀浆(100μl/动物,相当于15mg 15%脑匀浆)攻击两次。第一次和第二次攻击实验分别在DNA疫苗接种后76-83天和181天进行。作为内部阴性对照的一部分接种疫苗的动物(每组3-